REMS assessments found no cases of Torsades de pointes or unexplained sudden deaths among patients taking vandetanib during more than a decade of oversight, regulators said.
Medscape Medical News
Source link : https://www.medscape.com/viewarticle/fda-removes-rems-program-thyroid-cancer-drug-vandetanib-2025a1000pto?src=rss
Author :
Publish date : 2025-09-26 12:59:00
Copyright for syndicated content belongs to the linked Source.
